Search
Skip to Search Results- 1Al-Nuaimi, Saleem K
- 1Benson, Curtis A
- 1Guo, Huining
- 1Held, Morganne
- 1Hess, Scott L
- 1Huang, Yushan Yu Xiang
Results for "supervisors_tesim:"Baker, Glen (Psychiatry)""
-
Spring 2014
Major depression (MD) is one of the most prominent medical conditions worldwide in terms of societal cost and morbidity. MD has been associated with increased risk for cardiovascular disease (CVD) and conversely CVD has been associated with increased MD symptoms. Previous studies have shown that...
-
Neurochemical and neuroprotective aspects of phenelzine and its active metabolite B-phenylethylidenehydrazine
DownloadFall 2009
Phenelzine (PLZ) is a monoamine oxidase (MAO) inhibitor that also inhibits the activity of GABA-transaminase (GABA-T), causing significant and long-lasting increases in brain GABA levels. Inhibition of MAO prior to PLZ administration has been shown to prevent the GABAergic effects of the drug,...
-
The Antidepressant/Antipanic/Neuroprotective Drug Phenelzine: Neuropharmacological and Drug Metabolism Studies
DownloadSpring 2013
Phenelzine (PLZ) is a monoamine oxidase (MAO)-inhibiting antidepressant with anxiolytic and neuroprotective properties. Metabolites of PLZ were investigated in rat brain. Levels of phenylacetic acid (PAA) and β-phenylethylamine (PEA) were found to be elevated after administration of PLZ and PEH...
-
The interaction of phenelzine with human monoamine oxidase B: characterization and consequences
DownloadSpring 2022
Phenelzine (PLZ) is a monoamine oxidase (MAO) inhibitor developed in the 1960s which has been used clinically for psychiatric conditions such as depression and anxiety disorders. However, despite over 60 years of research, the mechanism by which PLZ exerts its effects on MAO has yet to be...
-
Spring 2016
Depression is a common, recurrent and frequently chronic mental health disorder that has already become one of the leading health-care burdens. Despite the wide clinical application of antidepressants, a significant portion of patients does not benefit sufficiently from the standard medication...
-
Hippocampal neuroplasticity and neurogenesis in major depressive disorder: a high field MRI study
DownloadFall 2012
The hippocampus is a brain structure responsible for memory, learning, and the stress response; it is also used as a model for major depressive disorder (MDD) in preclinical studies. Preclinical models have shown that the hippocampal subfields are differentially affected by chronic stress....
-
Exploring Novel Therapies for Motor and Non-Motor Symptoms in a Mouse Model of Multiple Sclerosis
DownloadSpring 2016
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by neurodegeneration, inflammation and demyelination. Symptoms of multiple sclerosis not only include motor deficits, but also secondary symptoms of pain, depression and anxiety. The purpose of...
-
Novel properties of the multifaceted drug phenelzine and its metabolite β-phenylethylidenehydrazine
DownloadFall 2015
Phenelzine is a monoamine oxidase (MAO) inhibitor that has been used for the treatment of depression and anxiety disorders since the 1960s. In recent years, there has been renewed interest in this drug following reports of its neuroprotective properties in animal models of cerebral ischemia,...
-
Plasma Levels of Neuroactive Steroids in Panic Disorder Patients and Healthy Volunteers Following Pentagastrin versus Placebo Injections
DownloadFall 2016
Panic disorder is an anxiety illness that can be quite debilitating and costly to society. To date there is no real cure for panic disorder and current methods of treatment are suboptimal. Given the level of morbidity and societal cost of panic disorder, further research and development of...